Data indicates from an experiment experience that people who use Mountjaro are able to maintain weight loss for three years.
Mounjaro, nicknamed “King Kong” for weight loss drugs, contains tirzepatide and is self -managed in injection once a week.
It works by imitation Two hormones are called GLP-1 and GIP, which leads to anorexia, increased insulin production, increased insulin sensitivity and a decrease in the rate in which food is emptied of the stomach. The drug is available for weight loss for some people on NHS and can also be purchased in particular with a prescription.
Scientists at Eli Lilly, the company that manufactures mounjaro, along with academic researchers, released two analysis of data from the three-year experience known as Surmount-1, with fresh light on the use of the drug in the long run. One of the analyzes of weight loss paths, and the second when the bounce after the initial weight.
The results to be presented at the European Conference obesity In málaga next month and has not yet been reviewed, it relies on data from about 700 participants who took Tirzepatide in three different dose systems during a 176 -week study. They were all obese or overweight and had a disease before diabetes.
The results reveal that the experiences of the participants tend to follow one of the three patterns – either fasted, medium or rapid weight, followed by a plateau, which later occurred as the first decrease. The team said that the average final body weight cuts of these groups were 9.2 %, 20.2 % and 30.8 %, respectively. Each group included about a third of the participants.
“[The work] “We can predict in one way or another to lose the final weight of the speed of weight loss that was observed in the first months of treatment,” said Professor Luka Posito, of the University of Badova in Italy, one of the scientists behind the first analysis.
The researchers said that most of the participants have maintained a clinical weight reduction throughout the study. This was supported by the second analysis, which was found that the average time to the lowest weight was 22 months, and at this point the participants lost 23.1 % of their weight on average.
While some people later regained weight – although continuing the drug – the participants nevertheless lost 19.4 % of their weight, on average, by the end of the study.
The team added that 70 % of the participants regained less than 5 % of the starting weight after they reached the lowest point.
Professor Nid Saturn, from the University of Glasgow, who did not participate in the experiment, said that finding different weight loss paths can help give a signal to the amount of weight that the individual may expect in the long run. He said: “This may be able to direct the need for some individuals to consider newer treatments, which are more effective, in the future.”
Dr. Simon Cork, from the University of Angela Roskin, said the other analysis showed a long -term event for Terzopatid in maintaining weight loss, which will be important for health bodies “with the costs of treating common diseases related to obesity on a general basis.”
Cork also indicated that the long -term safety and safety studies of such medications are now at odds with guidance, which limits their use to a maximum of two years.
The results come at a time when the Advertising Standards Authority announced that in addition to the organizational agency for pharmaceuticals and health care products and the General Council of Medicines, companies have warned against prohibiting medicines that suffer from a prescription for the public only. This includes weight loss strikes such as mounjaro, Wegovy and Saxenda.
Among other examples, the rules are covered on social media “such as photos or video ads on Facebook, Instagram and Tiktok”, Google or other search engines, and ads by influencers.
Achieving the guardian Previously detected This weight loss injection has been strongly marketed for British consumers through illegal promotions often.
